Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2010 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: kanamycin sulfate

« Back to Dashboard
Kanamycin sulfate is the generic ingredient in four branded drugs marketed by Apothecon, Hikma Maple , Abraxis Pharm, Fresenius Kabi Usa, Intl Medication, Loch, Pharmafair, Solopak, Warner Chilcott, Watson Labs, and King Pharms, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for kanamycin sulfate.

Summary for Generic Name: kanamycin sulfate

Drug Master File Entries: see list5
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Clinical Trials for: kanamycin sulfate

Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
Status: Completed Condition: Healthy

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
Status: Completed Condition: Tuberculosis

Patients Response to Early Switch To Oral:Osteomyelitis Study
Status: Not yet recruiting Condition: Osteomyelitis

Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics
Status: Completed Condition: Colorectal Neoplasms

High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
Status: Completed Condition: Tuberculosis, Multidrug-Resistant

Brief Bactericidal Activity of Anti-Tuberculosis Drugs
Status: Not yet recruiting Condition: Tuberculosis; Drug-resistant Tuberculosis; Multidrug-resistant Tuberculosis

Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
Status: Temporarily not available Condition: Tuberculosis

Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
Status: Active, not recruiting Condition: Mycobacterium Avium-Intracellulare Infection

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Status: Not yet recruiting Condition: Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
kanamycin sulfate
INJECTABLE; INJECTION062520-003May 9, 1985DISCNNo<disabled><disabled>
kanamycin sulfate
INJECTABLE; INJECTION062605-001Feb 26, 1986DISCNNo<disabled><disabled>
Abraxis Pharm
kanamycin sulfate
INJECTABLE; INJECTION062504-003Apr 5, 1984DISCNNo<disabled><disabled>
kanamycin sulfate
CAPSULE; ORAL061911-001Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
kanamycin sulfate
INJECTABLE; INJECTION062668-001May 7, 1987DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn